Movano Stock Surges 308% on AI Infrastructure Merger with Corvex

Merger Details and Stock Performance

Movano Inc. (NASDAQ:MOVE) experienced a dramatic surge in its stock price, jumping 308% to $19.22 on Monday following the announcement of a definitive all-stock merger agreement with Corvex Inc., an AI cloud computing company specializing in GPU-accelerated infrastructure 1

1

. The merger exchange ratio is based on a Movano per-share value of $6.25, with Corvex shareholders set to receive 46.6 million shares of Movano stock after accounting for concurrent financings 2

2

.

Strategic Transformation to AI Infrastructure

The strategic combination will fundamentally transform Movano from its current medical device focus into a pure-play platform concentrated on secure AI infrastructure and high-performance inference capabilities 1

1

. This positioning aims to capture the scaling demand in the AI sector through Corvex's Amplified AI Cloud platform, which addresses what the companies describe as the three defining challenges of the AI era: scale, efficiency, and security 2

2

.

Corvex's AI Technology Platform

Corvex specializes in GPU-accelerated infrastructure for AI workloads, offering comprehensive services including AI factories, GPU clusters, confidential computing, and inference-as-a-service 2

2

. The company's technology platform is designed to handle enterprise-scale AI computing demands, positioning the merged entity to compete in the rapidly expanding AI infrastructure market.

Financial Structure and Leadership

The companies have secured $40 million in aggregate concurrent private placement financing to support the new venture 1

1

. Upon closing, the combined company will be renamed "Corvex, Inc." with headquarters in Arlington, Virginia, and will be led by Corvex's management team, including Co-CEOs Seth Demsey and Jay Crystal 2

2

. The transaction structure will result in pre-merger Corvex stockholders owning approximately 96.2% of the combined company, while pre-merger Movano stockholders will retain approximately 3.8% .

Divestiture of Medical Device Operations

As part of the strategic pivot, Movano's legacy medical device operations, including the FDA-cleared EvieMED Ring and its proprietary mmWave RF technology for cuffless blood pressure and noninvasive glucose monitoring, will be marketed for sale 1

1

. Net proceeds from that sale, after satisfying certain obligations, may be distributed to pre-merger Movano shareholders 1

1

. The transaction is expected to close in the first quarter of 2026, subject to shareholder approvals and other customary closing conditions 2

2

.